利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.029 秒)

    NOVEL XYLANASE PRODUCED FROM CELLULOSIMICROBIUM FUNKEI HY-13
    1.
    发明申请
    NOVEL XYLANASE PRODUCED FROM CELLULOSIMICROBIUM FUNKEI HY-13 审中-公开
    来自蜂窝霉素FUNKEI HY-13的新型XYLANASE

    公开(公告)号：US20120309074A1

    公开(公告)日：2012-12-06

    申请号：US13577811

    申请日：2010-03-18

    申请人： Ho-Yong Park ,  Kwang-Hee Son ,  Do Young Kim ,  Tae-Sook Jeong ,  Sung Uk Kim ,  Dong-Ha Shin

    发明人： Ho-Yong Park ,  Kwang-Hee Son ,  Do Young Kim ,  Tae-Sook Jeong ,  Sung Uk Kim ,  Dong-Ha Shin

    IPC分类号： C12N9/24 ,  C12N1/19 ,  C12N5/10 ,  C12N1/21

    CPC分类号： C12N9/2482 ,  A23K10/14 ,  A23K20/189 ,  A23K50/30 ,  A23K50/75 ,  C12Y302/01008

    摘要： There are provided a novel xylanase and a use of the same. In detail, there are provided a xylanase separated from a Cellulosimicrobium funkei HY-13 strain, a Fibronectin Type 3 domain of the xylanase, and a use thereof. Since determining that the xylanase having substrate specificity degrades xylan at neutral and basic pH with high efficiency and the Fn3 domain does an important role with respect to the substrate specificity, the xylanase according to the present invention may be added to various vegetable feed materials or be efficiently used to improve degradation ability of cellulosic biomass.

    摘要翻译： 提供了一种新型的木聚糖酶及其用途。 详细地，提供了从纤维素微球菌HY-13菌株，木聚糖酶的纤连蛋白3型结构域分离的木聚糖酶及其用途。 由于确定具有底物特异性的木聚糖酶在中性和碱性pH下以高效率降解木聚糖，并且Fn3结构域在底物特异性方面起重要作用，根据本发明的木聚糖酶可以加入到各种植物饲料中，或者 有效地用于提高纤维素生物质的降解能力。

    PHARMACEUTICAL COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION OF LIVER DYSFUNCTION
    5.
    发明申请
    PHARMACEUTICAL COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION OF LIVER DYSFUNCTION 审中-公开
    含有ARAZYME用于预防肝功能障碍的药物组合物

    公开(公告)号：US20100322917A1

    公开(公告)日：2010-12-23

    申请号：US12521618

    申请日：2006-12-28

    申请人： Ho-Yong Park ,  Kwang-Hee Son ,  Dong-Ha Shin ,  Kyu-Shik Jeong

    发明人： Ho-Yong Park ,  Kwang-Hee Son ,  Dong-Ha Shin ,  Kyu-Shik Jeong

    IPC分类号： A61K38/48 ,  A61P1/16 ,  A61P35/00 ,  C12N9/52

    CPC分类号： A61K38/4886 ,  A23L33/10 ,  A23L33/135

    摘要： The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.

    摘要翻译： 本发明涉及一种用于预防肝功能障碍的药物组合物，其含有作为活性成分的阿拉木霉，更准确地说，涉及含有由Aranicola proteolyticus产生的arazyme的用于预防肝功能障碍的药物组合物。 本发明的arazyme抑制受损肝细胞凋亡，增加SMP30表达，抑制P-smad3表达，通过抑制中心静脉区域周围的肝损伤来保护肝脏。 因此，本发明的芳脒可以有效地用作预防肝功能障碍的药物组合物。

    COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION AND TREATMENT OF CANCER
    6.
    发明申请
    COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION AND TREATMENT OF CANCER 审中-公开
    含有ARAZYME用于预防和治疗癌症的组合物

    公开(公告)号：US20090317374A1

    公开(公告)日：2009-12-24

    申请号：US12521676

    申请日：2007-12-28

    申请人： Ho-Yong Park ,  Kwang-Hee Son ,  Dong-Ha Shin ,  Kyu-Shik Jeong

    发明人： Ho-Yong Park ,  Kwang-Hee Son ,  Dong-Ha Shin ,  Kyu-Shik Jeong

    IPC分类号： A61K38/48 ,  A61P35/00

    CPC分类号： A61K38/4886 ,  A23C15/065 ,  A23G1/423 ,  A23G3/366 ,  A23G4/123 ,  A23G9/363 ,  A23L2/02 ,  A23L2/66 ,  A23L13/424 ,  A23L13/48 ,  A23L23/00 ,  A23L33/19

    摘要： The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-κB and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL/lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

    摘要翻译： 本发明涉及一种用于预防和治疗癌症的药物组合物，其包含作为活性成分的胂酸盐。 更准确地说，当将Aranicola proteolycius产生的arazyme给予移植有人肺癌细胞系的裸鼠时，体重增加，抑制肿瘤细胞生长和浸润以及MMP-9，NF-κB和PCNA的下调均为 观察到的。 另外，当将arazyme处理到人乳腺癌细胞（MDA-MB-231）时，下调p21，PCNA（增殖细胞核抗原），VEGF（血管内皮生长因子），BCl2（B细胞CLL /淋巴瘤2 ），参与肿瘤细胞生长，分化，增殖和转移的p-p38，PKC（蛋白激酶C）和MMP-1（基质金属蛋白酶-1）以及抑制肿瘤发生的过氧化氢酶的上调 。 因此，可以有效地使用胂酸盐作为预防和治疗癌症的药物组合物。

    Pharmaceutical composition containing arazyme for the prevention of liver dysfunction
    7.
    发明授权
    Pharmaceutical composition containing arazyme for the prevention of liver dysfunction 有权
    含有arazyme用于预防肝功能障碍的药物组合物

    公开(公告)号：US08367060B2

    公开(公告)日：2013-02-05

    申请号：US13234847

    申请日：2011-09-16

    申请人： Ho-Yong Park ,  Kwang-Hee Son ,  Dong-Ha Shin ,  Kyu-Shik Jeong

    发明人： Ho-Yong Park ,  Kwang-Hee Son ,  Dong-Ha Shin ,  Kyu-Shik Jeong

    IPC分类号： A61K38/48

    CPC分类号： A61K38/4886 ,  A23L33/10 ,  A23L33/135

    摘要： The present invention relates to a composition and a method for the treatment of liver dysfunction which contains administration of a composition containing arazyme as an active ingredient, more precisely arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects the liver by inhibiting liver injury around the central vein region. Therefore, the arazyme of the invention can be effectively used as a composition for the treatment of liver dysfunction.

    摘要翻译： 本发明涉及一种治疗肝功能障碍的组合物和方法，其包含施用含有阿拉木霉作为活性成分的组合物，更准确地说是由Aranicola proteolyticus产生的arazyme。 本发明的arazyme抑制受损肝细胞凋亡，增加SMP30表达，抑制P-smad3表达，并通过抑制中心静脉区周围的肝损伤来保护肝脏。 因此，本发明的胂酸盐可以有效地用作治疗肝功能障碍的组合物。

    Composition Containing Arazyme for the Prevention and Treatment of Arthritis
    10.
    发明申请
    Composition Containing Arazyme for the Prevention and Treatment of Arthritis 审中-公开
    包含关于预防和治疗关节炎的疯狂的组合

    公开(公告)号：US20100278806A1

    公开(公告)日：2010-11-04

    申请号：US12812388

    申请日：2009-01-09

    申请人： Ho-Yong Park ,  Kwang-Hee Son ,  Dong-Ha Shin ,  Kyu-Shik Jeong

    发明人： Ho-Yong Park ,  Kwang-Hee Son ,  Dong-Ha Shin ,  Kyu-Shik Jeong

    IPC分类号： A61K38/48 ,  A61P19/02

    CPC分类号： A61K38/4886

    摘要： Disclosed herein is a composition containing arazyme as an active ingredient for prevention and treatment of arthritis. More specifically, arazyme produced from Aranicola proteolyticus of the present invention may be useful as a composition for prevention and treatment of arthritis by inhibiting the expression of TNF-α which is an inflammation-inducing factor and preventing the loss of proteoglycan and collagen from joint cartilage to inhibit the progression of arthritis and protect joints.

    摘要翻译： 本文公开了含有作为预防和治疗关节炎的活性成分的阿拉木霉的组合物。 更具体地说，本发明的由Aranicola proteolyticus产生的arazyme可用作通过抑制作为炎性诱导因子的TNF-α的表达来预防和治疗关节炎的组合物，并防止蛋白聚糖和胶原从关节软骨中的损失 抑制关节炎的进展并保护关节。